Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides

WHO's new End TB Strategy

The Lancet · 2015 · 987 citations

Pulmonary Tuberculosis, Tuberculosis Prevention, Global Challenge +4

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

Kévin Pethe, Pablo Bifani, Jichan Jang et al. · Nature Medicine · 2013 · 595 citations · Full text

Medicinal Chemistry, Potent Clinical Candidate, Pulmonary Tuberculosis +7

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9

Design, Synthesis, and Structure–Activity Correlations of Novel Dibenzo[<i>b</i>,<i>d</i>]furan, Dibenzo[<i>b</i>,<i>d</i>]thiophene, and <i>N</i>-Methylcarbazole Clubbed 1,2,3-Triazoles as Potent Inhibitors of <i>Mycobacterium tuberculosis</i>

Santhosh Reddy Patpi, Lokesh Pulipati, Perumal Yogeeswari et al. · Journal of Medicinal Chemistry · 2012 · 216 citations

Click Chemistry, Chemistry, Heterocycle Chemistry +18

Lead Optimization of a Novel Series of Imidazo[1,2-<i>a</i>]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

Sun‐Hee Kang, Ryang Yeo Kim, Min Jung Seo et al. · Journal of Medicinal Chemistry · 2014 · 173 citations · Full text

Pharmaceutical Science, Bioorganic Chemistry, Extensively-drug-resistant Anti-tuberculosis Agent +18